Cargando…
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by deficient expression of estrogen, progesterone, and human epidermal growth factor receptor 2 receptors. These patients are therefore not give...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Breast Cancer Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769384/ https://www.ncbi.nlm.nih.gov/pubmed/31598336 http://dx.doi.org/10.4048/jbc.2019.22.e39 |
_version_ | 1783455230592024576 |
---|---|
author | Nakhjavani, Maryam Hardingham, Jennifer E Palethorpe, Helen M Price, Tim J Townsend, Amanda R |
author_facet | Nakhjavani, Maryam Hardingham, Jennifer E Palethorpe, Helen M Price, Tim J Townsend, Amanda R |
author_sort | Nakhjavani, Maryam |
collection | PubMed |
description | Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by deficient expression of estrogen, progesterone, and human epidermal growth factor receptor 2 receptors. These patients are therefore not given the option of targeted therapy and have worse prognosis as a result. Consequently, much research has been devoted to identifying specific molecular targets that can be utilized for targeted cancer therapy, thereby limiting the progression and metastasis of this invasive tumor, and improving patient outcomes. In this review, we have focused on the molecular targets in TNBC, categorizing these into targets within the immune system such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets. The aim of this review is to introduce and summarize the known targets and drugs under investigation in phase II or III clinical trials, while introducing additional possible targets for future drug development. This review brings a tangible benefit to cancer researchers who seek a comprehensive comparison of TNBC treatment options. |
format | Online Article Text |
id | pubmed-6769384 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Breast Cancer Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-67693842019-10-09 Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer Nakhjavani, Maryam Hardingham, Jennifer E Palethorpe, Helen M Price, Tim J Townsend, Amanda R J Breast Cancer Review Article Breast cancer (BC) is still the most common cancer among women worldwide. Amongst the subtypes of BC, triple negative breast cancer (TNBC) is characterized by deficient expression of estrogen, progesterone, and human epidermal growth factor receptor 2 receptors. These patients are therefore not given the option of targeted therapy and have worse prognosis as a result. Consequently, much research has been devoted to identifying specific molecular targets that can be utilized for targeted cancer therapy, thereby limiting the progression and metastasis of this invasive tumor, and improving patient outcomes. In this review, we have focused on the molecular targets in TNBC, categorizing these into targets within the immune system such as immune checkpoint modulators, intra-nuclear targets, intracellular targets, and cell surface targets. The aim of this review is to introduce and summarize the known targets and drugs under investigation in phase II or III clinical trials, while introducing additional possible targets for future drug development. This review brings a tangible benefit to cancer researchers who seek a comprehensive comparison of TNBC treatment options. Korean Breast Cancer Society 2019-09-02 /pmc/articles/PMC6769384/ /pubmed/31598336 http://dx.doi.org/10.4048/jbc.2019.22.e39 Text en © 2019 Korean Breast Cancer Society https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Nakhjavani, Maryam Hardingham, Jennifer E Palethorpe, Helen M Price, Tim J Townsend, Amanda R Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
title | Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
title_full | Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
title_fullStr | Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
title_full_unstemmed | Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
title_short | Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer |
title_sort | druggable molecular targets for the treatment of triple negative breast cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769384/ https://www.ncbi.nlm.nih.gov/pubmed/31598336 http://dx.doi.org/10.4048/jbc.2019.22.e39 |
work_keys_str_mv | AT nakhjavanimaryam druggablemoleculartargetsforthetreatmentoftriplenegativebreastcancer AT hardinghamjennifere druggablemoleculartargetsforthetreatmentoftriplenegativebreastcancer AT palethorpehelenm druggablemoleculartargetsforthetreatmentoftriplenegativebreastcancer AT pricetimj druggablemoleculartargetsforthetreatmentoftriplenegativebreastcancer AT townsendamandar druggablemoleculartargetsforthetreatmentoftriplenegativebreastcancer |